Kinetics and Biotransformation of Adrenergic Activators and Inhibitors: Adrenergic Alpha- and Beta-Receptor Activators

  • K. H. Rahn
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 54 / 2)


Etilephrine (Fig. 1) is a sympathomimetic used almost exclusively by oral administration for the treatment of hypotension. Its distribution in the rat and its disposition in humans have been studied by Hengstann et al. (1975).


Oral Dose Total Radioactivity Fetal Heart Rate Unchanged Drug Peak Plasma Level 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Baving, G., Ulmer, W.T.: Die Dosis-Wirkungs-Relation von peroral verabreichtem Orciprenalin bei obstruktiven Atemwegserkrankungen. Arzneim. Forsch. 20, 1083–1088 (1970)Google Scholar
  2. Bennett, P., Blackwell, E., Davies, D.S.: Metabolism of drugs by intestinal mucosa - effect of salicylamide on bio-availability of oral isoprenaline in dogs. Abstracts VI. International Congress of Pharmacology, Helsinki, 1975, p. 583Google Scholar
  3. Bergman, J., Persson, H., Wetterlin, K.: Two new groups of selective stimulants of adrenergic beta-receptors. Experientia 25, 899–901 (1969)PubMedCrossRefGoogle Scholar
  4. Blackwell, E.W., Conolly, M.E., Davies, D.S., Dollery, C.T.: The fate of isoprenaline administered by pressurized aerosols. Br. J. Pharmacol. 39, 194P–195P (1970)PubMedGoogle Scholar
  5. Bogner, R.L., Walsh, J.M.: Sustained-release principle in human subjects utilizing radioactive techniques. J. Pharmac. Sci. 53, 617–620 (1964)CrossRefGoogle Scholar
  6. Brogden, R.N., Speight, T.M., Avery, G.S.: Terbutaline aerosol (bricanyl): an independent re-port. Med. Progr. Technol. 7, 19–21 (1974)Google Scholar
  7. Bruce, R.B., Pitts, J.E.: The determination and excretion of phenylephrine in urine. Biochem. Pharmacol. 17, 335–337 (1968)CrossRefGoogle Scholar
  8. Capecchi, V., Cavalli, F., Falcoone, F., Fasano, E.: Comparison of terbutaline and salbutamol aerosols in patients with bronchial asthma. Int. J. Clin. Pharmacol. Biopharm. 16, 310–312 (1978)PubMedGoogle Scholar
  9. Cavalitto, C.J., Chafetz, L., Miller, L.D.: Some studies of a sustained release principle. J. Pharmac. Sci. 52, 259–263 (1963)CrossRefGoogle Scholar
  10. Chester, E.H., Doggett, W.E., Montenegro, H.D., Schwartz, H.J., Jones, P.K.: Bronchodilating effect of terbutaline aerosol. Clin. Pharmacol. Ther. 23, 630–634 (1978)PubMedGoogle Scholar
  11. Choo-Kang, Y.F.J., Simpson, W.T., Grant, I.W.B.: Controlled comparison of the bronchodilator effects of three beta-adrenergic stimulant drugs administered by inhalation to patients with asthma. Br. Med. J. 2, 287–289 (1969)PubMedCrossRefGoogle Scholar
  12. Choo-Kang, Y.F.J., McDonald, H.C., Harne, N.W.: A comparison of salbutamol and terbutaline aerosols in bronchial asthma. Pactitioner 211, 801–804 (1973)Google Scholar
  13. Conolly, M.E., Davies, D.S., Dollery, C.T., George, C.F.: Resistance to ß-adrenoeeptor stimulants (a possible explanation for the rise in asthma deaths). Br. J. Pharmacol. 43, 389–402 (1971)PubMedGoogle Scholar
  14. Conolly, M.E., Davies, D.S., Dollery, C.T., Morgan, C.D., Paterson, J.W., Sandler, M.: Metabolism of isoprenaline in dog and man. Br. J. Pharmacol. 46, 458–472 (1972)PubMedGoogle Scholar
  15. Conway, W.D., Minatoya, H., Lands, A.M., Shekosky, J.M.: Absorption and elimination profile of isoprenaline. III. J. Pharmac. Sci. 57, 1135–1141 (1968)CrossRefGoogle Scholar
  16. Conway, W.D., Singhvi, S.M., Gibaldi, M., Boyes, R.N.: The effect of route of administration on the metabolic fate of terbutaline in the rat. Xenobiotica 3, 813–821 (1973)PubMedCrossRefGoogle Scholar
  17. Davies, D.S., George, C.F., Blackwell, E., Conolly, M.E., Dollery, C.T.: Metabolism of terbutaline in man and dog. Br. J. Clin. Pharmacol. 1, 129–136 (1974)Google Scholar
  18. Dengler, HJ., Hengstmann, J.H.: Metabolism and pharmacokinetics of orciprenaline in various animal species and man. Arch. Int. Pharmacodyn. Ther. 223, 71–87 (1976)PubMedGoogle Scholar
  19. Dollery, C.T., Davies, D.S., Conolly, M.E.: Differences in the metabolism of drugs depending upon their route of administration. Arch. Int. Pharmacodyn. Ther. 192, Suppl., 214–219 (1971)Google Scholar
  20. Formgren, H.: A clinical comparison of the effects of oral terbutaline and orciprenaline. Scand. J. Respir. Dis. 51, 195–202 (1970)PubMedGoogle Scholar
  21. Freedman, B.J.: Trial of a new bronchodilator, terbutaline, in asthma. Br. Med. J. 1, 633–636 (1971)PubMedCrossRefGoogle Scholar
  22. Freedman, B.J.: Trial of terbutaline aerosol in the treatment of asthma and comparison of its effects with those of a salbutamol aerosol. Br. J. Dis. Chest. 66, 222–229 (1972)PubMedCrossRefGoogle Scholar
  23. Hengstmann, J.H., Dengler, H.J.: Pharmacokinetic properties and metabolism of phenolic sympathomimetic amines in man. Abstracts VI. International Congress of Pharmacology, Helsinki 1975, p. 451Google Scholar
  24. Hengstmann, J.H., Weyand, U., Dengler, H.J.: The physiological disposition of etilefrine in man. Eur. J. Clin. Pharmacol. 9, 179–187 (1975)PubMedCrossRefGoogle Scholar
  25. Hertting, G.: The fate of 3H-iso-proterenol in the rat. Biochem. Pharmacol. 13, 1119–1128 (1964)PubMedCrossRefGoogle Scholar
  26. Holzbauer, M., Sharman, D.F.: The distribution of catecholamines in vertebrates. In: Catecholamines. Blaschko, H., Muscholl, E. (eds.), pp. 110–185. Berlin, Heidelberg, New York: Springer 1972Google Scholar
  27. Hüter, J., Rippert, C., Meyer, C.: Wehenhemmung mit welchem Beta-Mimetikum (Berotec®, Ritodrine®, Dilatol®)? Geburtshilfe Frauenheilkd. 32, 97–103 (1972)PubMedGoogle Scholar
  28. Jung, H., Abramowski, P., Klöck, F.K., Schwenzel, W.: Zur Wirkung alpha- und beta-adrenergischer Substanzen am menschlichen Uterus und Nebenwirkungen auf Mutter und Kind. Geburtshilfe Frauenheilkd. 31, 11–27 (1971)PubMedGoogle Scholar
  29. Kadar, D., Lovrics, A.J., Endrenyi, L.: The fate of (7-3H)isoproterenol in cats after intravenous administration. Drug. Metab. Dispos. 6, 476–480 (1978)PubMedGoogle Scholar
  30. Kennedy, M.C.S.: Simpson, W.T.: Human pharmacological and clinical studies on salbutamol: A specific beta-adrenergic bronchodilator. Br. J. Dis. Chest. 63, 165–174 (1969)PubMedCrossRefGoogle Scholar
  31. Kopin, I.J.: Metabolic degradation of catecholamines. The relative importance of different pathways under physiological conditions and after administration of drugs. In: Catecholamines. Blaschko, H., Muscholl, E. (eds.), pp. 270–282. Berlin, Heidelberg, New York: Springer 1972Google Scholar
  32. Kords, H.: Kreislaufwirkungen, Placentapassage, Pharmakokinetik und Metabolismus von Fenoterol (Partusisten) beim trächtigen Meerschweinchen. Z. Geburtshilfe Perinatol. 179, 30–36 (1975)PubMedGoogle Scholar
  33. Kramer, I., Klingspohr, H.J.: Ganztierautoradiographische Untersuchungen über die Verteilung und die diaplazentare Passage von Fenoterol-hydrobromid (Th 1165 a) an Ratten. Arzneim. Forsch. 24, 1210–1213 (1974)Google Scholar
  34. Künzel, W., Reinecke, J.: Der Einfluß von Th 1165 a auf die Gaspartialdrucke und auf kardiovaskuläre Parameter von Mutter und Fetus. Zugleich eine quantitative Analyse der Wehentätigkeit. Z. Geburtshilfe Perinatol. 177, 81–90 (1973)PubMedGoogle Scholar
  35. Legge, J.S., Gaddie, J., Palmer, K.N.V.: Comparison of two oral selective beta-adrenergic stimulant drugs in bronchial asthma. Br. Med. J. 1, 637–639 (1971)PubMedCrossRefGoogle Scholar
  36. Lin, C., Li, Y., McGlotten, J., Morton, J.B., Symchowicz, S.: Isolation and identification of the major metabolite of albuterol in human urine. Drug Metab. Dispos. 5, 234–238 (1977)PubMedGoogle Scholar
  37. Martin, L.E., Hobson, J.C., Page, J.A., Harrison, C.: Metabolic studies of salbutamol-3H: A new bronchodilator, in rat, rabbit, dog, and man. Eur. J. Pharmacol. 14, 183–199 (1971)PubMedCrossRefGoogle Scholar
  38. Meissner, J., Klostermann, H.: Distribution and diaplacental passage of infused 3H-fenoterol hydrobromide (Partusisten®) in the gravid rabbit. Int. J. Clin. Pharmacol. 13, 27–35 (1976)Google Scholar
  39. Meissner, J., Preil, P.: Untersuchungen über Verteilung und Passage von T-markiertem Fenoterol-hydrobromid (Th 1165 a) am trächtigen und laktierenden Kaninchen. Arzneim. Forsch. 24, 1213–1217 (1974)Google Scholar
  40. Minatoya, H., Lands, A.M., Portmann, G.A.: Absorption and elimination profile of isoproterenol. I. Anesthetized Dogs. J. Pharmac. Sci. 54, 968–972 (1965 a)CrossRefGoogle Scholar
  41. Minatoya, H., Lands, A.M., Portmann, G.A.: Absorption and elimination profile of isoproterenol. II. Parenteral, oral, and rectal administration to unanaesthetized dogs. J. Pharmac. Sci. 54, 973–978 (1965 b)CrossRefGoogle Scholar
  42. Morgan, C.D., Ruthven, C.R.J., Sandler, M.: The quantitative assessment of isoprenaline metabolism in man. Clin. Chim. Acta 26, 381–386 (1969 a)PubMedCrossRefGoogle Scholar
  43. Morgan, CD., Sandler, M., Davies, D.S., Conolly, M., Paterson, J.W., Dollery, C.T.: The metabolic fate of DL-(7-3H)isoprenaline in man and dog. Clin. Chim. Acta 26, 381–386 (1969 b)PubMedCrossRefGoogle Scholar
  44. Mosler, K.H.: Probleme der Wehenhemmung durch Pharmaka. Med. Klin. 64, 133–139 (1969)PubMedGoogle Scholar
  45. Neville, A., Palmer, J.B.D., Gaddie, J., May, C.S., Palmer, K.N.V., Murchison, L.E.: Metabolic effects of salbutamol: comparison of aerosol and intravenous administration. Br. Med. J. 1, 413–414 (1977)PubMedCrossRefGoogle Scholar
  46. Nilsson, H.T., Persson, K., Tegner, K.: The metabolism of terbutaline in man. Xenobiotica 2, 363–373 (1972)PubMedCrossRefGoogle Scholar
  47. Nolte, D.: Das Verhalten von Atemwegs-Resistance und intrathorakalem Gasvolumen nach Inhalation eines Hydroxyphenyl-Derivates des Orciprenalin (Th 1165 a). Respiration 27, 396–405 (1970)PubMedCrossRefGoogle Scholar
  48. Paterson, J.W., Conolly, M.E.: The clinical pharmacology of inhaled isoprenaline. Proc. Int. Soc. Drug Toxicol. 12, 138–141 (1971)Google Scholar
  49. Paterson, J.W., Conolly, M.E., Davies, D.S., Dollery, C.T.: Isoprenaline resistance and the use of pressurized aerosols in asthma. Lancet 2, 426–429 (1968)PubMedCrossRefGoogle Scholar
  50. Persson, K., Persson, K.: The metabolism of terbutaline in vitro by rat and human liver O-methyltransferases and monoamine oxidases. Xenobiotica 2, 375–382 (1972)PubMedCrossRefGoogle Scholar
  51. Philippot, E., Bacq, Z.M., Sulman, E.G.: Actions du 1(3-méthoxy-4-oxyphényl)-1-hydroxy-2- isopropylamino-éthane(3-méthoxy-isoprotérénol). Arch. Int. Pharmacodyn. Ther. 156, 234–237 (1965)Google Scholar
  52. Reichl, R., Traunecker, W., Engelhardt, A.: Quantitative pharmacological investigations with 3-methoxy-isoprenaline, the primary metabolite of isoprenaline. Proc. Eur. Soc. Drug Tox. 12, 142–146 (1971)Google Scholar
  53. Rominger, K.L., Pollmann, W.: Vergleichende Pharmakokinetik von Fenoterol-Hydrobromid bei Ratte, Hund und Mensch. Arzneim. Forsch. 22, 1190–1196 (1972)Google Scholar
  54. Ryrfeldt, A., Bodin, N.O.: The physiological disposition of ibuterol, terbutaline and isoproterenol after endotracheal instillation to rats. Xenobiotica 5, 521–529 (1975)PubMedCrossRefGoogle Scholar
  55. Ryrfeldt, A., Nilsson, E.: Uptake and biotransformation of ibuterol and terbutaline in isolated perfused rat and guinea pig lungs. Biochem. Pharmacol. 27, 301–305 (1978)PubMedCrossRefGoogle Scholar
  56. Sandler, M.: Catecholamine synthesis and metabolism in man: clinical implications (with special reference to Parkinsonism). In: Catecholamines. Blaschko, H., Muscholl, E. (eds.), pp. 845–899. Berlin, Heidelberg, New York: Springer 1972Google Scholar
  57. Seyberth, H.W., Rahn, K.H.: Pharmakokinetische Untersuchungen am Menschen mit einem als Dosier-Aerosol verwendeten Beta-Sympathomimetikum. Verh. Dtsch. Ges. Inn. Med. 79, 888–891 (1973)PubMedGoogle Scholar
  58. Shenfield, G.M., Evans, M.E., Paterson, J.W.: Absorption of drugs by the lung. Br. J. Clin. Pharmacol. 3, 583 (1976)Google Scholar
  59. Speizer, E.E., Doll, R., Heaf, P.: Observations on recent increase in mortality from asthma. Br. Med. J. 1, 335–339 (1968 a)PubMedCrossRefGoogle Scholar
  60. Speizer, E.E., Doll, R., Heaf, P., Strang, L.B.: Investigation into use of drugs preceding death from asthma. Br. Med. J. 7, 339–343 (1968 b)CrossRefGoogle Scholar
  61. Stockhausen, H., Schnell, J., Rüther, K.: Die Tokolyse unter der Geburt - eine tokographische Vergleichsuntersuchung bei Anwendung verschiedener tokolytischer Substanzen. Geburtshilfe Frauenheilkd. 7, 51–56 (1972)Google Scholar
  62. Tatsumi, K., Yamato, C., Arima, N., Yoshimura, H., Tsukamoto, H.: Metabolism of drugs. LXVIII. Metabolie fate of metaproterenol. Yakugaku Zasshi 90, 639–643 (1970)PubMedGoogle Scholar
  63. Tatsumi, K., Arima, N., Yoshimura, H.: Metabolism of drugs. LXXIV. Metabolie fate of metaproterenol. Yakugaku Zasshi 97, 680–683 (1971)Google Scholar
  64. Trautlein, J., Allegra, J., Gillin, M.: A long term study of low dose aerosolized terbutaline sulfate. J. Clin. Pharmacol. 16, 361–366 (1976)PubMedGoogle Scholar
  65. Ulmer, W.T., Podiesch, I., Heede, C.: Objektivierung von Therapieerfolgen bei chronisch obstruktivem Emphysem. Verh. Dtsch. Ges. Inn. Med. 71, 964–969 (1968)Google Scholar
  66. Walker, S.R., Evans, M.E., Richards, A.J., Paterson, J.W.: The clinical pharmacology of oral and inhaled salbutamol. Clin. Pharmacol. Ther. 13, 861–867 (1972)PubMedGoogle Scholar
  67. Warrell, D.A., Robertson, D.G., Newton Howes, J., Conolly, M.E., Paterson, J.W., Beilin, L.J., Dollery, C.T.: Comparison of cardiorespiratory effecs of isoprenaline and salbutamol in patients with bronchial asthma. Br. Med. J. 1, 65–70 (1970)PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1981

Authors and Affiliations

  • K. H. Rahn

There are no affiliations available

Personalised recommendations